Abstract: A generating device for simulating a particulate environment for an experimental animal includes an experimental chamber. An ultrasonic atomization device is installed at the bottom adjacent to the center of the experimental chamber. The upper side of the ultrasonic atomization device is connected to a guide device for guiding particles. The guide device includes an air seal cover, and a micro fan is installed inside the air seal cover to drive the movement of particles generated in the ultrasonic atomization device. Air guide pipes are fixedly connected to a side wall of the air seal cover. The generating device has good sealing performance, and can generate a variety of particle simulation environments to accurately and effectively simulate the biological effect of particles in the animal body. The generating device can improve the particle simulation environment, reduce the deviation of experimental data, and ensure the accuracy of the overall experimental data.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: A communication method integrated with trustworthiness measurement, including: a first network element sends a first data packet, where the first data packet includes first request information, and the first request information is used to request to verify whether a second network element is trusted. The first network element receives a second data packet, where the second data packet includes first response information, and the first response information is used to verify whether the second network element is trusted.

Abstract: This application provides a communication method integrated with trusted measurement and an apparatus. The method includes: A first network element sends a first request message, where the first request message is for requesting to verify whether terminal device is trusted. The first network element receives a first response message, where the first response message is for verifying whether the terminal device is trusted.

Abstract: A method includes: a network function service consumer sends a service request message, where the service request message is used to request to obtain a service provided by a network function service provider. The network function service consumer receives a service response message, where the service response message indicates whether the service request message is accepted, and further indicates a result of trustworthiness verification of the network function service consumer. The method helps the network function service provider verify, before providing the network service, an identity of the network function service consumer and determine whether the network function service consumer is trusted, to help improve security of communication between core network elements and improve security of a core network device.

Abstract: A trusted attestation method and a communication apparatus are provided. The method includes: A first node obtains information about a first blockchain, and the first node determines attestation information based on the information about the first blockchain. The attestation information is used to remotely attest whether the first node is trusted. The information about the first blockchain may be used as a common random number that is generated by the first blockchain based on a consensus and that can be used by a plurality of nodes. Therefore, the information about the first blockchain may be used as a challenge value for performing security measurement by the plurality of nodes. The attestation information may be verified by any verifier to implement measurement for one time and verification for a plurality of times, so that the first node does not need to establish a separate “challenge-response” procedure with each verifier.

Abstract: Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or modulating a DDB1- and CUL4-associated factor 1 (DCAF1) protein. Further provided herein are ligand-DCAF1 complexes or in vivo modified DCAF1 proteins.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: Provided are bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof, and methods for identifying such bivalent compounds.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Abstract: This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Abstract: This disclosure relates to GSPT1 degrader compounds (e.g. small molecule compounds), compositions comprising one or more of the compounds, and to methods of use the compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such compounds.

Abstract: A display panel includes a substrate, a plurality of light-emitting devices, a first encapsulation layer, and a first dielectric layer. The first encapsulation layer includes a first portion and a second portion at least partially surrounding the first portion. The first dielectric layer is located between the first encapsulation layer and the plurality of light-emitting devices. Along the direction perpendicular to the plane of the display panel, a distance between a surface of the first portion away from at least one light-emitting device of the plurality of light emitting devices and a surface of the third portion away from the at least one light-emitting device is smaller than a distance between a surface of the second portion away from the at least one light-emitting device and a surface of the fourth portion away from the at least one light-emitting device.

Abstract: This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Abstract: A generating device of simulating a particulate environment for an experimental animal includes an experimental chamber. An ultrasonic atomization device is installed at the bottom adjacent to the center of the experimental chamber. The upper side of the ultrasonic atomization device is connected to a guide device for guiding particles. The guide device includes an air seal cover, and a micro fan is installed inside the air seal cover to drive the movement of particles generated in the ultrasonic atomization device. Air guide pipes are fixedly connected to a side wall of the air seal cover. The generating device has good sealing performance, and can generate a variety of particle simulation environments to accurately and effectively simulate the biological effect of particles in the animal body. The generating device can improve the particle simulation environment, reduce the deviation of experimental data, and ensure the accuracy of the overall experimental data.

Abstract: This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Abstract: Bivalent compounds composition comprises one or more of the bivalent compounds. The bivalent compound comprises a cyclic-AMP response element binding protein (CBP) and/or adenoviral EA binding protein of 300 kDa (P300) ligand (CBP/P3000 ligand) conjugated to a degradation tag. The method of using the bivalent compounds is treating certain disease in a subject in need thereof. The method of identifying such bivalent compounds is disclosed.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Abstract: According to an example, key splitting may include utilizing a masked version of a master key that is masked by using a mask.